This prospective study was intended to assess the clinical features and concentrations of selected mediators of apoptosis and inflammation, and immunoexpression of Ki67 and selected mediators of inflammation in patients with PCa after prostatectomy procedures, patients who underwent palliative radiotherapy for bone metastases, and patients with BPH. Here, MKI67 is linked to benign prostatic hyperplasia.